GlassScriptPhysician profile
Kenneth B Bielinski
NPI 1457306649
$2,799.24
in general payments reported to CMS, 2019-2025
31 companies · $31.20 in 2025
The $31.20 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $209 · 2021: $815 · 2022: $405 · 2023: $166 · 2025: $31.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $577.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $423.22 | 2019-2023 | |
| Abbvie INC. | $367.26 | 2019-2023 | Botox |
| Misonix INC | $288.88 | 2021 | |
| Bioventus LLC | $176.45 | 2021-2022 | |
| Janssen Biotech, INC. | $142.37 | 2019-2022 | |
| Pfizer INC. | $107.60 | 2019-2023 | |
| Genentech USA, INC. | $97.84 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.02 | 2019-2022 | |
| Amgen INC. | $47.35 | 2019-2025 | Otezla |
| Organogenesis INC. | $46.04 | 2022 | |
| Celgene Corporation | $44.89 | 2019 | |
| Galderma Laboratories, L.P. | $44.67 | 2019-2020 | |
| Leo Pharma INC. | $41.68 | 2021-2022 | |
| Lilly USA, LLC | $38.44 | 2019-2023 | Taltz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $36.47 | 2019 | |
| Incyte Corporation | $27.82 | 2022 | |
| Epi Health, LLC | $26.29 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $25.75 | 2021 | |
| Ucb, INC. | $23.07 | 2021 | |
| Allergan, INC. | $22.42 | 2022 | |
| Sun Pharmaceutical Industries INC. | $18.43 | 2020 | |
| Aclaris Therapeutics, INC. | $17.03 | 2019 | |
| Smith+Nephew, INC. | $16.58 | 2023 | Grafix Pl |
| Prugen, INC. Pharmaceuticals | $16.26 | 2020 | |
| Mission Pharmacal Company | $16.05 | 2019 | |
| Strata Skin Sciences, INC. | $15.96 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.77 | 2019 | |
| Almirall LLC | $13.16 | 2021 | |
| Biofrontera INC. | $8.12 | 2019 | |
| Glenmark Therapeutics INC. | $8.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bielinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.